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Background: In resource-limited settings, many patients, with no
prior protease inhibitor (PI) treatment on a second-line, high genetic
barrier, ritonavir-boosted PI-containing regimen have virologic
failure.
Methods: We conducted a cross-sectional survey to investigate the
aetiology of virologic failure in 2 public health antiretroviral clinics in
South Africa documenting the prevalence of virologic failure
(HIV RNA load .500 copies/mL) and genotypic antiretroviral
resistance; and lopinavir hair and plasma concentrations in a nested
case–control study.
Results: Ninety-three patients treated with a second-line regimen
including lopinavir boosted with ritonavir were included, of whom
50 (25 cases, with virologic failure and 25 controls) were included in
a nested case control study. Of 93 patients, 37 (40%) had virological
failure, only 2 of them had had major PI mutations. The negative
predictive values: probability of failure with lopinavir plasma
concentration .1 mg/mL or hair concentrations .3.63 ng/mg for
virologic failure were 86% and 89%, and positive predictivevalues of
low concentrations 73% and 79%, respectively, whereas all virologic
failures with HIV RNA loads above 1000 copies per milliliter, of
patients without PI resistance, could be explained by either having
a low lopinavir concentration in plasma or hair.
Conclusions: Most patients who fail a lopinavir/ritonavir regimen,
in our setting, have poor lopinavir exposure. A threshold plasma
lopinavir concentration (indicating recent lopinavir/ritonavir use)
and/or hair concentration (indicating longer term lopinavir exposure)
are valuable in determining the aetiology of virologic failure and
identifying patients in need of adherence counselling or resistance
testing.
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INTRODUCTION
Adult HIV-infected patients in resource-limited settings
who qualify for antiretroviral therapy (ART) are started on
a ﬁrst-line nonnucleoside reverse transcriptase inhibitor
(NNRTI) –based regimen.
1,2 Lamivudine, a nucleoside reverse
transcriptase inhibitor (NRTI) commonly used in ﬁrst-line
regimens, and NNRTIs both have low genetic barriers to
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resistance.
3–5 Therefore, if patients do not have adequate
adherence to this ﬁrst-line regimen, antiretroviral (ARV)
resistance can arise rapidly resulting in virologic failure
6 and
necessitating a switch to second-line therapy agents. The
recommended second-line ART regimen in resource-limited
settings is one composed of dual NRTIs and a ritonavir (RTV)
-boosted protease inhibitor (PI), typically lopinavir/ritonavir
(LPV/r).
2,7
LPV/r has a high genetic barrier to resistance.
8 However,
both LPV/r and didanosine, which until recently was one of
the NRTIs recommended in combination second-line regi-
mens, are commonly associated with gastrointestinal side
effects,
9,10 which can limit this regimen’s tolerability.
The prevalence of failure in patients on a second-line
regimen has been reported to be as high as 33% in South
African patients on LPV/r-based regimens.
11 Unlike virolog-
ical failure on an NNRTI regimen, very few patients who fail
a LPV/r-based regimen have resistance to LPV/r, provided
they have not had prior exposure to PIs.
11–13 This suggests that
most second-line virologic failures are due to inadequate
adherence rather than viral resistance.
13 Because the appro-
priate management of patients, failing second-line therapy
depends on the underlying aetiology of failure, it is important
to distinguish inadequate drug exposure (likely due to
adherence lapses) from ARV resistance. The identiﬁcation
of patients with poor drug exposure can limit unnecessary
genotypic ARV resistance testing (GART), which is costly,
enabling GART to be reserved for those who fail despite
adequate drug exposure. This selective use of GART could aid
in the choice of the next optimal regimen, either through using
currently available drugs, or by guiding the choice of third-line
regimen agents, once newer ARVs become accessible in
resource-limited settings.
Self-report or pill counts are the adherence measure-
ments used most often by ART programs in resource-limited
settings, but both measures tend to overestimate adherence.
14
Measuring drug concentrations or therapeutic drug monitoring
has the potential to provide an objective estimate of adherence.
Trough or random lopinavir (LPV) plasma concentrations
reﬂect recent adherence as the plasma half-life of LPVused in
a LPV/r formulation is 5–6 hours, whereas LPV concen-
trations in hair specimens estimates longer term exposure.
Recently, hair specimens havebeen used to measure ARV drug
exposure, using techniques of liquid chromatography coupled
with tandem mass spectrometry,
15 and PI concentrations in




We conducted a cross-sectional study of virologic failure
in adult patients on a second-line LPV/r-containing regimen.
Patients were consecutively enrolled at Tygerberg Hospital
Family Clinic and Ubunthu Clinic in Khayelitsha, Cape Town.
Adult patients on a second-line LPV/r-containing regimen, for
at least 1 month, who gave informed consent, were eligible for
inclusion into the study. Basic demographic information,
blood specimens for HIV-1 RNA load and LPV plasma
concentrations, and hair specimens for LPV and ritonavir
measurement were collected. Genotypic resistance testing was
done in patients with HIV-1 RNA loads .500 copies per
milliliter. Genotypic resistance testing was funded as part of
a larger descriptive study and was performed at the Tygerberg
Laboratory. However, as we had limited funding available and
hair analysis was only available at a remote laboratory in San
Francisco, California, we chose a nested case–control design
as the most efﬁcient strategy to evaluate the value of hair and
plasma LPV concentrations. The recruitment target was 25
cases and 25 controls. Patients were included in the nested
case–control study, based on having an appropriate matched
control, matched by age and gender in the clinic. Patients were
individually matched for gender and paired with the closest
available age match; with a window of not more than 5 years,
we could include 19 patients only; another 6 patients were
included on the basis of a age difference no more than 8 years.
Patientswere onlyexcluded from thecase–control studyon the
basis of not having a suitable match or having insufﬁcient
specimens for testing.
Patients whose hair was too short to cut using 2
ﬁngertips to hold it were excluded from hair analysis. The
study was approved by the Stellenbosch University Committee
for Human Research.
Hair was collected from the occipital area, as it has the
lowest variability in hair growth rate.
17,18 At least 25 strands
(3–4 mm tuft) of hair was cut as close to the scalp as possible.
The distal end was clearly marked with tape because the
proximal part of the specimen is expected to yield concen-
trations most reﬂective of recent exposure. The hair specimens
were wrapped in aluminum foil to avoid excessive light
exposure and stored at room temperature in a plastic bag with
desiccant until analysis.
For any particular patient, all specimens (HIV viral load,
genotypic resistance test, hair LPV concentration, and plasma
LPV concentration) were collected concurrently at a single
clinic visit.
Laboratory Methods
For viral load testing, we used the NucliSENS EasyQ
HIV-1 version 2.0 (bioMe ´rieux Boxtel, Netherlands). For the
purpose of this study, we deﬁned virologic failure as having
a viral load .500 HIV-1 RNA copies per milliliter plasma
because this is the sensitivity threshold for GART to be
performed using the in-house assay. ARV resistance testing
was done byan in-housevalidated genotypic polymerase chain
reaction and sequencing method, which has been described in
prior publications.
19,20
LPV plasma concentration was measured by tandem
liquid chromatography–mass spectrometry (University of
Cape Town, Clinical Pharmacology laboratory). As it was
logistically not possible to collect trough specimens for LPV
concentration measurement, a random specimen was collected,
along with the time of the last dose.
Hair LPVand ritonavir concentrations were measured by
liquid chromatography and tandem mass spectroscopy at the
University of California, San Francisco, using a modiﬁed
method.
15,16 The LPV and RTV in each hair specimen was
extracted with MeOH/FTA(9/1), then analyzed by the
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copy machine. Approximately 2 mg of proximal hair was
analyzed. The other conditions were identical to the published
methods article by the same group.
15
Statistics
The statistical analysis was performed using STATA
version 10.0. For comparison of the medians of matched data,
the Wilcoxon signed rank test was used and for categorical
data Fisher exact test was used. To describe the association
between LPV plasma or hair concentrations and failure, we
used conditional logistic regression to calculate odds ratios
and 95% conﬁdence intervals (CIs). We selected LPV hair and
plasma cut-off concentrations with receiver operating charac-
teristics, choosing cut-offs that maximized the sum of
sensitivity and speciﬁcity. When investigating the number of
cases and controls categorized according to a cut-off LPV
plasma or hair concentration, we deﬁned a LPV concentration
above the cut-off, which indicates adequate therapy exposure,
as ‘‘negative’’ and a concentration below this cut-off, which
would be expected to predict virologic failure, as ‘‘positive’’.
RESULTS
From the ﬁrst study site, Tygerberg Hospital Family
Clinic, we identiﬁed 99 patients on a LPV/r second-line
regimen in the clinic database, of whom wewere able to ask 77
patients to join the study; of them, 70 were eligible and agreed
to participate. From the second study site, Ubunthu Clinic,
Khayelitsha, we recruited patients attending 2 sequential clinic
visits dedicated to patients failing a second-line LPV/r
regimen; 25 patients were asked to join, and all 24 were
included as they were eligible and agreed to participate. In
total, 94 patients were thus included and specimens, de-
mographic information, and clinical information were col-
lected. In 1 patient, viral load testing failed and was thus
excluded. Thirty-seven of the 93 patients (40%; 95% CI: 30%
to 50%) had virologic failure, deﬁned as having an HIV-1
RNA load of .500 copies per milliliter. Seven patients were
taking rifampicin-containing antituberculosis therapy, 5 of
these patients had virologic failure, 2 of whom were not using
appropriately adjusted doses of LPV/r. Although more patients
on concurrent treatment for tuberculosis (TB) failed than those
not on TB therapy, this difference was not statistically
signiﬁcant (Fisher exact test: P = 0.11). Resistance testing
was unsuccessful in 4 of the 37 patients with virologic failure.
Of the 33 patients who had resistance tests, 28 patients had no
resistance to anyof the ARV drugs in their current regimen and
5 patients had resistance mutations to the current regimen.
Only 2 patients had major PI resistance mutations. Both
patients also had NRTI mutations (Table 1).
Of the 93 patients studied, 50 were included in the nested
case–control study: 25 cases (with virologic failure) and 25
controls. For 19 matched pairs, an age match with an age
difference between 1 and 5 years were available, another 6 pairs
were included who had an age difference of 6–8 years. The
group ages were well matched as the mean age difference
between the case and control groupswas 0.3years. Theresults of
the cases and control patients are summarized in Table 2. LPV
plasma concentrations, LPV hair concentrations, and RTV hair
concentrations were lower in patients with virological failure
compared with controls. Patients with virologic failure also had
a shorter duration of therapy and signiﬁcantly lower concurrent
CD4 counts than controls (Table 2).
Although we recruited 25 cases and controls, hair
specimens were available in 19 cases and 19 controls only, as
many patients had shaven their hair too short (Table 2). LPV
plasma concentrations and LPV hair and RTV hair concen-
trations were compared in patients with or without virological
failure. There was a clear separation of LPV hair and plasma
concentrations between patients with or without virologic
failure. However, RTV hair concentrations (Table 2) were not
clearly separated between those with and without virologic
failure. The odds ratio and 95% CI of virological failure for
each 5 mg/mL decrease in LPV plasma concentration was 2.1
(95% CI: 1.2 to 3.6) and 71.9 (95% CI: 0.6 to 8518.2) for each
5 ng/mg decrease in LPV hair concentration. In post hoc
analysis the inclusion of hair LPV concentrations, in addition
to plasma LPV concentrations, provided a better model—as
evident from a lower score according to Akaike information
criterion of 11.5 versus 26.4. Receiver operating characteristic
optimal cut-offs (that maximised the sum of sensitivity and
speciﬁcity for predicting failure) were a LPV plasma
concentration below 1 mg/mL and hair LPV concentration
below 3.63 ng/mg (Table 3). These LPV plasma and LPV hair
concentrations had respective calculated negative predictive
values (NPVs) of 86% and 89%, and calculated positive
predictive values of 73% and 79% when the prevalence of
virologic failure is 40%. A scatterplot of LPV hair and plasma
concentrations is shown in Figure 1. Thirty-one percent
patients had viral loads .1000 copies; at this prevalence and
viral load threshold, the calculated NPV for LPV plasma and
TABLE 1. Patients With Clinically Significant Resistance Mutations to Current Regimen
Patient Number PI Mutations NRTI Mutations Plasma HIV-RNA Load LPV-Plasma LPV-Hair
99 I54V, V82A M184V 13 000 10.3 NAV
32 L10F, L23F, M46I, I54V, T74S, V82A D67N, T69N, K70R, M184V, T215F, K219Q 5 500 NAV NAV
12 T74S D67N 940 BLD 0.97
74 T74S D67N, T69N 3700 NAV NAV
109 None M41L, M184V T215FIST 35 000 BLD NAV
BLD, below limit of detection (,0.2 mg/mL); LPV-plasma, LPV-plasma concentration in mg/mL; LPV-hair, LPV hair concentration in ng/mg hair; NAV, Not available; Plasma HIV
RNA load: copies per milliliter.
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plasma concentrations were not affected by timing of the blood
specimens as there was no association with taking the last
LPV/r dose the previous day or the same morning and having
a concentration below or above the cut-off (Fisher exact test:
P = 1.0). Amongst patients with virological failure, 6 had LPV
plasma concentrations above the cut-off (that is false negative
LPV concentrations—Table 3). Three of the 6 patients with
high LPV plasma concentrations had low LPV hair concen-
trations, suggesting a mechanism for failure (good short-term
exposure, but poor long-term exposure). Two others had viral
loads below 1000 copies per milliliter and could be excluded
from the false negatives as classiﬁed by LPV plasma or hair
concentrations by changing the viral load threshold to 1000
copies (Table 3). The only remaining patient with failure
despite high LPV plasma concentrations, number 99, had
signiﬁcant PI and NRTI resistance (Tables 1 and 3). Also at
a viral load threshold of 1000 copies per milliliter, the only
remaining patient with failure despite a high LPV-hair
concentration (Table 3) had a LPV plasma concentration
below the limit of detection—suggesting omission of recent
doses as an explanation of failure. Of the case–control group,
the only patients with concurrent rifampicin therapy for TB
were cases whose LPV plasma and hair concentrations were
both below the respective cut-offs.
DISCUSSION
We observed a very high rate of virologic failure (40%)
in patients on a second-line LPV/r-based regimen in our
setting, which was even higher than another study from South
Africa that reported a failure a prevalence of 33%.
11 Virologic
failure increases the risk of disease progression and death.
21
Poor drug exposure, most likely due to inadequate adherence,
was the major cause of ARV failure in our study. However, 2 of
the 33 patientswho had resistance tests had major PI resistance
mutations, despite the fact that this was their ﬁrst PI exposure.
The 2 patients with major PI mutations also had NRTI
mutations. As expected, the CD4 count was lower in patients
with virologic failure compared with controls. Patients with
virologic failure had a shorter history of LPV/r therapy than
controls, this could, however, not be explained by insufﬁcient
time to allow suppression as the shortest second-line therapy
duration was 2 months and the interquartile range was 9–21.5
months. As there are currently no third-line options available
in most resource-limited settings, patients are often retained on
the second-line regimen irrespective of having virological
failure. PI resistance mutations in patients on a boosted PI
regimen usually occur at a low rate with moderate levels of
adherence.
22 Therefore, although the rate of acquisition of PI
resistance mutations is low, it is likely that the number of
patients with signiﬁcant PI resistance will accumulate over
time in resource-limited settings, resulting in a growing
TABLE 2. Descriptive Statistics of Demographic and Clinical Characteristics of Patients Included in the Case–Control Study
Descriptive Statistics:Median (IQR) (Except for Gender)
Factor Nonfailure (n = 25) (VL , 500 copies/mL) Failure (n = 25) (VL . 500 copies/mL) P
Age (yrs) 38 (34–3) 36 (30–46) NA (matching criterion)
Gender Female = 16 Female = 16 NA (matching criterion)
CD4 count (cells/mL) 297 (236–544) 168 (105–227) 0.0069
Log10VL (Log10 copies/mL) ,1 4.1 (3.0–5.5) NA (matching criterion)
BMI 24.5 (22.1–26.1) 24.1 (21.3–29.6) 0.322
Duration of LPV therapy (months) 28 (13–44) 11.5 (9–21.5) 0.0217
LPV-plasma (mg/mL) 10.2 (6.31–12.70) 0 (0–0.81) 0.0037
LPV-hair (ng/mg) 8.36 (5.63–12.13), (n = 19) 0.97 (0.27–3.15), (n = 19) 0.0009
RTV-hair (ng/mg) 0.81 (0.46–1.22), (n = 19) 0.13 (0.04–0.54), (n = 19) 0.0084
The P values are from Signed rank test.
BMI, body mass index; IQR, interquartile range; NA, not applicable; RTV , ritonavir; VL, HIV-1 RNA load.







LPV plasma concentration ,1 mg/mL as predictive
of virological failure using an HIV RNA
cut-off of 500 copies/mL
,1 mg/mL 1 19 20
.1 mg/mL 24 6 30
Total 25 25 50
LPV plasma concentration ,1 mg/mL as predictive
of virologic failure using an HIV RNA cut-off
of 1000 copies/mL
,1 mg/mL 4 16 20
.1 mg/mL 27 3 30
Total 31 19 50
LPV hair concentration ,3.63 ng/mg as predictive
of virologic failure using an HIV RNA cut-off of
500 copies/mL
,3.63 ng/mg 2 16 18
.3.63 ng/mg 17 3 20
Total 19 19 38
LPV hair concentration ,3.63 ng/mg as predictive of
virologic failure using an HIV RNA cut-off of
1000 copies/mL
,3.63 ng/mg 5 13 18
.3.63 ng/mg 19 1 20
Total 24 14 38
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better-tolerated ARVs, as is recommended in the current
updated World Health Organization’s guidelines,
7 may
improve adherence and therefore decrease the proportion of
failures.
LPV plasma and hair concentrations and RTV hair
concentrations were all signiﬁcantly lower in patients with
virological failure relative to controls. We found cut-off LPV drug
concentrations for plasma and hair that could discriminate
between failure and nonfailure. Using aviral load failure criterion
of 1000 copies per milliliter, a LPV plasma concentration ,1
mg/mL and LPV hair concentration of ,3.63 ng/mg had NPVs
for virologic failure of 92% and 96%, respectively. In a further
exploration of the false-negative cases (patients with either a high
LPV plasma concentration or hair concentration, whilst having
virologic failure), all cases except one could be explained by
having poor drug exposure, as was evident from either having
a low LPV plasma or hair concentration, the remaining case of
failure had major PI and NRTI resistance.
We therefore propose a diagnostic algorithm (Fig. 2) that
includes viral load measurement, random LPV plasma, and
hair concentration measurement to identify patients who are
likely to have virologic failure due to genotypic resistance and
not poor adherence. At the outset of the study, we deﬁned
virologic failure as .500 copies per milliliter as this allowed
us to do resistance testing. However, a criterion of sustained
viral load above 1000 copies per milliliter is used to deﬁne
failure in the South African public sector, and although a viral
load between 50 and 1000 copies per milliliter would warrant
clinical attention, such as adherence counseling, it would not
indicate the need for a therapy change in patients on a high
genetic barrier second-line regimen. At a viral load threshold
of 1000 copies per milliliter, a random LPV plasma
concentration ,1 mg/mL or hair concentration ,3.63 ng/mg
due to their excellent NPV could exclude patients with poor
drug exposure from unnecessary costly ARV resistance
testing. Indeed, patients with a LPV or hair concentration
below the threshold can be targeted for adherence interven-
tions with repeat viral load testing at a follow-up visit.
Although GART could be performed at HIV-1 RNA loads of
below 1000 copies, commercial assays are only licensed to
detect resistance above this threshold and the intensive
investigation of patients treated with such a high genetic
barrier regimen with low-level viremia may not be cost
effective. In the algorithm we suggest only analyzing LPV
concentrations in hair and plasma in patients with viral loads
above 1000 copies per milliliter. The proposed algorithm will
be less costly than GART for patients failing second-line
regimens as the cost of a plasma LPV concentration
measurement is about US $27 and hair measurement US
$40, whereas GART typically cost from US $250 to US $530
in the South African setting. The beneﬁt of using a random
plasma concentration and a hair concentration, in combination,
is that a low plasma concentration would indicate ‘‘recent’’ poor
adherence and a lowhairconcentration,measuredin a 1-cm hair
specimen, ‘‘average’’ poor adherence over a period of about 1
month, as hair grows at about 1–1.5 cm per month, even when
the recent adherence as indicated by a high plasma LPV
concentration may be adequate (but too short to suppress viral
replication). These tests therefore could also provide some
insight in the adherence patterns of patients. A low random
plasma concentration, in the absence of trough measurements,
proved to be informative as most patients with virologic failure
had very low random plasma LPV concentrations.
Our study was explorative with a few limitations as
follows: (1) the cross-sectional design did not enable us to
longitudinally monitor the effect of LPVexposure onvirologic
failure; (2) due to logistical reasons we measured random LPV
concentrations rather than trough concentrations, which could
have been more accurate; (3) our study was limited by small
sample size; (4) a ﬁnal limitation is that stable patients are
referred out to primary clinics which could result in a selection
bias with a higher LPV failure rate in the study population
compared with other settings, as problematic patients are often
retained in care.
CONCLUSIONS
We found a very high prevalence of virologic failure
amongst adult patients in our South African setting on a LPV/
based regimen. The majority failed due to poor drug exposure,
most likely related to poor adherence, as was evident from
either a low LPV plasma or hair concentration. Therefore, the
use of plasma and hair LPV concentrations could be valuable
in diagnosing the cause of virologic failure and allow targeted
GARTonly in those patients where failure is not explained by
poor drug exposure.
FIGURE 1. Scatterplot of Lopinavir hair (ng/mg) and plasma
concentrations [(mg/mL) in patients with virologic failure
(triangles) and nonfailure patients (open circles)]. The dashed
lines indicate the respective concentration cut-offs: LPV
plasma concentration of 1 mg/mL and LPV hair concentration
of 3.63 ng/mg.
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